Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 19/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL30957789 | 0.99 | NLRP3 (0.63) | NLRP3EGFRERBB2 | |
| SCHEMBL22867163 | 0.94 | NLRP3 (0.64) | NLRP3EGFRERBB2 | |
| Potassium SCHEMBL30957790 | 0.93 | NLRP3 (0.63) | NLRP3EGFRERBB2 | |
| SCHEMBL22866871 | 0.91 | NLRP3 (0.63) | NLRP3 | |
| Potassium SCHEMBL30957776 | 0.90 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL22866630 | 0.90 | NLRP3 (0.64) | NLRP3 | |
| SCHEMBL22867150 | 0.90 | NLRP3 (0.67) | NLRP3EGFRERBB2 | |
| SCHEMBL22867094 | 0.90 | NLRP3 (0.67) | NLRP3 | |
| SCHEMBL22866611 | 0.89 | NLRP3 (0.68) | NLRP3 | |
| Potassium SCHEMBL30957796 | 0.89 | NLRP3 (0.66) | NLRP3EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885EGFR 4153/4885ERBB2 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.